News & Insight

adverse events from immune checkpoint inhibitors
December 21, 2023/News & Insight

Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

23-CNR-4274330-CQD-Hero-650×450
October 18, 2023/News & Insight

Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023/News & Insight

Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023/News & Insight

Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023/News & Insight

Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

23-CNR-4185077-CQD-Hero-650×450
August 31, 2023/News & Insight

CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

outreach to underserved communities
June 2, 2023/News & Insight

Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust

prostate cancer
May 5, 2023/News & Insight

Lutetium-PSMA for Metastatic Prostate Cancer (Podcast)

FDA-approved therapy offers promise for patients with castrate-resistant prostate cancer

22-CNR-3155332-CQD-Hero-650×450 Dr Adjei
August 30, 2022/News & Insight

Taussig Cancer Institute Chair Brings New Vision for Clinical Research

Breaking through barriers in cancer care

BackPage 1 of 23Next
Advertisement
Ad